Vimarsana
Biggest News Aggregation in the World

Page 2 - Memed Key News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Memed Key. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Memed Key Today - Breaking & Trending Today

Maccabi Healthcare Services announces it is the first HMO - Vimarsana News

Maccabi Healthcare Services announces it is the first HMO

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care Groundbreaking host-response...

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV test as part of routine care - Vimarsana News

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV test as part of routine care

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV test as part of routine care Groundbreaking host-response test distinguishes between bacterial

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio - Vimarsana News

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio GlobeNewswire January 10, 2022 MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed Contacts:Media: Will Harris, VP Marketing, MeMedpr@me-med.com IR: Kfir Emmer, CFO, MeMedkfir.emmer@me-med.comMedia Contacts:Consilium Strategic CommunicationsMeMed@consilium-comms.com

MeMed raises $93 million to translate the immune system - Vimarsana News

MeMed raises $93 million to translate the immune system

The Israeli company recently received FDA approval for its MeMed BV test to help healthcare providers distinguish between bacterial and viral infections

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio - Vimarsana News

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV test recently cleared for use by US FDA to aid in distinguishing between bacterial and